Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients

Ben Bulten, H.J. Verberne, L. Bellersen, W.J. Oyen, A. Sabate-Llobera, A.M. Mavinkurve-Groothuis, L. Kapusta, H.W. van Laarhoven, Lioe-Fee de Geus-Oei

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Scopus)
58 Downloads (Pure)


Purpose It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated 123I-metaiodobenzylguanidine (123I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and several biomarkers. Methods We performed 123I-mIBG scintigraphy, conventional and strain echocardiography and biomarker (NT-proBNP, TNF-α, galectin-3, IL-6, troponin I, ST-2 and sFlt-1) assessment in 59 breast cancer survivors 1 year after anthracycline treatment. Interobserver and intermethod variability was calculated on planar and SPECT 123I-mIBG scintigraphy, using the heart/mediastinum (H/M) ratio and washout (WO). Pearson’s r and multivariate analyses were performed to identify correlations and independent predictors of 123I-mIBG scintigraphy results. Results Delayed planar anterior whole-heart ROI (WH) H/M ratios and WO were the most robust 123I-mIBG parameters. Significant correlations were observed between 123I-mIBG parameters and several conventional echo parameters, global longitudinal and radial strain (GLS and GRS) and galectin-3. The highest Pearson’s r was observed between delayed H/M ratio and GRS (Pearson’s r 0.36, p = 0.01). Multivariate analysis showed that GRS was the only independent predictor of the delayed WH H/M ratio (p = 0.023). Conclusion The delayed planar H/M ratio is the most robust 123I-mIBG parameter. It correlates with several conventional echocardiographic parameters, GLS, GRS and galectin-3. Of these, only GRS predicts the H/M ratio.
Original languageUndefined
Pages (from-to)957-967
Number of pages11
JournalCancer chemotherapy and pharmacology
Issue number5
Publication statusPublished - 2015


  • METIS-313399
  • IR-99830

Cite this